ClinicaliQ Trial Snapshot
- Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT — Recruiting • Phase III • Cardiology / Cardiovascular • NCT07764978.
- What is being tested: AZD0120 (a novel therapeutic agent) as consolidation/maintenance therapy following standard induction regimens (IsaVRd or DRd) compared to continuous standard therapy (IsaRd or DRd) in newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation.
- Patient eligibility overview: Adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation, meeting standard disease and organ function criteria for chemotherapy-based treatment.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT) as initial therapy.
Eligibility Snapshot
- :
- Participants must be 18 years or older, at the time of signing the ICF.
- Participant must have documented diagnosis of MM according to the IMWG diagnostic criteria.
- Participant must have one or more of the following measurable disease criteria: (a) Serum M-protein level ≥1.0 g/dL, (b) Urine M-protein level ≥ 200 mg/24 h, (c)Serum immunoglobulin FLC ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda FLC ratio.
- Participant must be deemed ineligible for ASCT while also having adequate organ function for CAR-T cell treatment.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.